News Sentiment

OMER sentiment intelligence

Omeros Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 44 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.28 Week of 10 Jul 2026
Weighted tone 44/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+10.8% over one week, +17.7% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 10.8% Price confirming higher
Trend fit Trend inactive 17.7% over four weeks
Fair value 63.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 18

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
TradingView 7
simplywall.st 5
Stocktwits 4
Pluang 3
Investing.com 3
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 14
Regulatory and legal 12
Deals and strategy 3
Analyst action 2
Capital return 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
Stocktwits Direct company coverage

Why Is OMER Stock Falling Today?

Omeros Corporation (OMER) stock is falling today after European regulators issued a negative opinion on its therapy, Yartemlea, for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The European Medicines Agency (EMA) found insufficient evidence of the dru

Tone
Negative 18/100
Event
Market update
Published
26 Jun 2026 12:39
Source
Stocktwits